Medicare Wants to Cover CBD for Seniors — and Prohibitionists Are Suing to Stop It

The federal government wants to give Medicare beneficiaries up to $500 a year to buy hemp-derived CBD products. A coalition of prohibitionist groups is fighting to make sure that never happens. The resulting legal battle, now heading toward a preliminary injunction hearing scheduled for April 20 — yes, 4/20 — may determine whether cannabis-derived products can enter the mainstream American healthcare system through its largest payer.

The Program at the Center of the Fight

In December 2025, the Trump administration publicly announced the creation of a Centers for Medicare and Medicaid Services reimbursement program for hemp-derived products. The program, called the Substance Access Beneficiary Engagement Incentive, allows eligible Medicare beneficiaries to receive up to $500 annually in qualifying hemp-derived CBD and THC products through three CMS Innovation Center models.

The concept is rooted in a practical reality that healthcare policymakers have been grappling with for years. Millions of seniors use CBD products to manage chronic pain, anxiety, insomnia, and inflammation — conditions that are pervasive in the Medicare population and that conventional pharmaceutical treatments often address with medications carrying significant side effects. Opioids, benzodiazepines, and sleep medications prescribed to seniors contribute to falls, cognitive impairment, dependency, and drug interactions that generate billions in additional healthcare costs.

The CMS pilot represents an attempt to bring hemp-derived products into the supervised healthcare framework. Rather than having seniors purchase CBD on their own — often from unregulated online retailers without professional guidance — the program would channel those purchases through a regulated system with quality standards and professional oversight.

An FDA enforcement memo cleared the way for the program by establishing a framework for hemp CBD product quality standards within the pilot. This addressed one of the key regulatory obstacles: the FDA's longstanding position that CBD cannot be marketed as a dietary supplement because of its status as an active pharmaceutical ingredient in Epidiolex.

The Lawsuit

On April 1, 2026, Smart Approaches to Marijuana (SAM) and allied prohibitionist organizations filed a federal lawsuit to block the program's implementation. The complaint raises several legal arguments against the CMS pilot.

The plaintiffs allege that CMS unlawfully adopted the Substance Access BEI in violation of the Administrative Procedure Act by bypassing the required notice-and-comment rulemaking process. Federal agencies are generally required to publish proposed rules, solicit public comments, and respond to those comments before implementing new programs — a process that CMS allegedly shortcut in launching the pilot.

Second, the lawsuit argues that CMS acted "arbitrarily and capriciously" by implementing a program that contradicts a prior CMS rule indicating that marijuana and marijuana-derived products would not be covered by Medicare. The plaintiffs contend that even though the pilot covers hemp-derived products (which are federally legal under the 2018 Farm Bill), the program conflicts with CMS's stated position on cannabis-related coverage.

Third, the complaint alleges that CMS exceeded its statutory authority. The plaintiffs argue that Congress never authorized CMS to use Innovation Center models to provide coverage for products that have not gone through the FDA's drug approval process.

The Court's Initial Response

On April 1, the court denied the plaintiffs' emergency motion for a temporary restraining order, finding that they had not met the high legal standard required for such relief. A temporary restraining order requires showing an immediate, irreparable harm that justifies blocking government action before the case can be fully argued — a standard the court determined the plaintiffs had not satisfied.

However, the denial of the TRO doesn't end the matter. The court will next consider a preliminary injunction motion, with briefing due on April 9 and a hearing scheduled for April 20. A preliminary injunction is a somewhat lower bar than a TRO, though it still requires the plaintiffs to demonstrate a likelihood of success on the merits and a balance of harms that favors blocking the program.

The April 20 hearing date is coincidental but symbolically loaded — a legal battle over cannabis healthcare access being argued on the most recognized cannabis holiday in the world.

Who's Behind the Challenge

Smart Approaches to Marijuana, the lead plaintiff, is a nonprofit founded in 2013 by former federal drug policy advisor Kevin Sabet and former congressman Patrick Kennedy. The organization has positioned itself as a centrist voice opposing commercialized cannabis legalization while supporting medical research and decriminalization.

In practice, SAM has been one of the most active opponents of cannabis normalization at the state and federal level, campaigning against ballot initiatives, lobbying against legislative reform, and challenging regulatory frameworks that expand cannabis access. The organization's involvement in the Medicare lawsuit is consistent with its broader strategy of using legal and political channels to slow cannabis integration into mainstream systems.

The coalition's opposition to the CMS pilot reflects a philosophical position: that cannabis-derived products, even those that are federally legal like hemp CBD, should not enter the healthcare system without going through the FDA's full drug approval process. It's a position that carries some scientific logic — the FDA approval process ensures safety and efficacy through rigorous clinical trials — but critics argue it ignores the reality that millions of seniors are already using these products without any oversight at all.

What's Actually at Stake for Seniors

The human dimension of this legal battle often gets lost in procedural arguments about administrative law. Approximately 67 million Americans are enrolled in Medicare, and a significant portion of them already use or are interested in CBD products.

Chronic pain is the primary driver. Arthritis affects more than half of adults over 65, and conventional pain management options for seniors are limited. NSAIDs carry risks of gastrointestinal bleeding and kidney damage. Opioids carry risks of dependency, falls, and respiratory depression. CBD, while not a cure-all, has a favorable safety profile and growing evidence supporting its use for inflammatory pain.

Sleep disorders are another major use case. Insomnia affects up to half of older adults, and the benzodiazepines and Z-drugs commonly prescribed for sleep carry risks of next-day drowsiness, cognitive impairment, and falls — risks that are particularly dangerous for seniors. CBD's anxiolytic and sleep-promoting properties have made it an attractive alternative for older adults seeking better sleep without pharmaceutical side effects.

The CMS pilot would provide these seniors with financial support to purchase quality-controlled products through a supervised system — replacing the current reality where they buy products of unknown quality from unregulated sources without medical guidance.

The Regulatory Paradox

The lawsuit exposes a fundamental paradox in how the American healthcare system handles cannabis-derived products. Hemp CBD is federally legal. Millions of Americans use it. A growing body of research supports its efficacy for several conditions common in the Medicare population. Yet the healthcare system's largest payer has, until this pilot, treated it as if it doesn't exist.

This creates an absurd gap. Medicare will cover prescription opioids that carry significant risks of addiction and overdose. It will cover sleep medications that increase fall risk in seniors. But it won't cover a hemp-derived product with a relatively benign safety profile because that product hasn't gone through an FDA approval process that was designed for synthetic pharmaceuticals.

The CMS Innovation Center was created specifically to test new payment models and healthcare delivery approaches. Using it to pilot cannabis-derived product coverage falls within its mandate, at least according to the administration's legal interpretation. The lawsuit will ultimately test whether that interpretation holds up in court.

Industry and Market Implications

The outcome of this case has significant implications beyond Medicare policy. If the CMS pilot survives legal challenge and produces positive outcomes — reduced opioid use, improved pain management, better sleep quality among participants — it could create a template for broader cannabis integration into the American healthcare system.

Private insurers, which often follow Medicare's lead on coverage decisions, would face increasing pressure to consider CBD coverage. State Medicaid programs, which serve even more vulnerable populations, could develop similar pilot programs. And the precedent of a federal agency providing reimbursement for hemp-derived products would accelerate the normalization of cannabis in healthcare settings.

Conversely, if the lawsuit succeeds and the pilot is blocked, it would reinforce the regulatory barriers that keep cannabis-derived products outside the healthcare system, regardless of their legal status or the evidence supporting their use. It would also embolden legal challenges to other cannabis-friendly federal initiatives.

The Bigger Picture

The Medicare CBD lawsuit is part of a broader tension playing out across American policy in 2026: the collision between cannabis normalization and the institutional structures that were built during prohibition. Healthcare, insurance, banking, housing, and employment all contain embedded policies that assume cannabis is dangerous and illegal. As the legal landscape changes, those policies are being challenged — sometimes through legislation, sometimes through executive action, and sometimes through lawsuits like this one.

The April 20 hearing will produce a legal ruling on administrative procedure and statutory authority. But the broader question it raises is more fundamental: in a country where cannabis is legal in most states, where millions of seniors use CBD products, and where the evidence base is growing, how long can the healthcare system justify pretending these products don't exist?

That question will outlast this lawsuit, regardless of how the court rules. And for the 67 million Americans on Medicare, the answer matters more than any legal argument about notice-and-comment rulemaking.